Kosiorek Piotr, Kazberuk Dorota Elżbieta, Hryniewicz Anna, Milewski Robert, Stróż Samuel, Stasiak-Barmuta Anna
Department of Emergency, Maria Sklodowska-Curie Bialystok Oncology Centre, Ogrodowa 12, 15-027 Białystok, Poland.
Department of Clinical Immunology, Medical University of Białystok, Jana Kilińskiego 1, 15-089 Białystok, Poland.
Vaccines (Basel). 2022 Feb 19;10(2):334. doi: 10.3390/vaccines10020334.
Systemic vaccination with the BNT162b2 mRNA vaccine stimulates the humoral response. Our study aimed to compare the intensity of the humoral immune response, measured by SARS-CoV-2 IgG, SARS-CoV-2 IgM, and S-RBD-neutralizing IgG antibody levels after COVID-19 vaccination versus after SARS-CoV-2 infection. We analyzed 1060 people in the following groups: convalescents; healthy unvaccinated individuals; individuals vaccinated with Comirnaty, AstraZeneca, Moderna, or Johnson & Johnson; and vaccinated SARS-CoV-2 convalescents. The concentrations of SARS-CoV-2 IgG, SARS-CoV-2 IgM, and S-RBD-neutralizing antibodies were estimated in an oncology hospital laboratory by chemiluminescent immunoassay (CLIA; MAGLUMI). Results: (1) We observed a rise in antibody response in both the SARS-CoV-2 convalescent and COVID-19-vaccinated groups. (2) The levels of all antibody concentrations in vaccinated COVID-19 convalescents were significantly higher. (3) We differentiated asymptomatic SARS-CoV-2 convalescents from the control group. Our analysis suggests that monitoring SARS-CoV-2 IgG antibody concentrations is essential as an indicator of asymptomatic COVID-19 and as a measure of the effectiveness of the humoral response in convalescents and vaccinated people. Considering the time-limited effects of post-SARS-CoV-2 infection recovery or vaccination and the physiological half-life, among other factors, we suggest monitoring IgG antibody levels as a criterion for future vaccination.
使用BNT162b2 mRNA疫苗进行全身接种可刺激体液免疫反应。我们的研究旨在比较COVID-19疫苗接种后与SARS-CoV-2感染后，通过SARS-CoV-2 IgG、SARS-CoV-2 IgM和S-RBD中和IgG抗体水平测量的体液免疫反应强度。我们分析了以下几组的1060人：康复者；未接种疫苗的健康个体；接种了Comirnaty、阿斯利康、Moderna或强生疫苗的个体；以及接种了疫苗的SARS-CoV-2康复者。在一家肿瘤医院实验室通过化学发光免疫分析（CLIA；MAGLUMI）估计SARS-CoV-2 IgG、SARS-CoV-2 IgM和S-RBD中和抗体的浓度。结果：（1）我们观察到SARS-CoV-2康复组和COVID-19疫苗接种组的抗体反应均有所上升。（2）接种疫苗的COVID-19康复者中所有抗体浓度水平均显著更高。（3）我们将无症状SARS-CoV-2康复者与对照组区分开来。我们的分析表明，监测SARS-CoV-2 IgG抗体浓度对于作为无症状COVID-19的指标以及作为康复者和接种疫苗者体液免疫反应有效性的衡量标准至关重要。考虑到SARS-CoV-2感染康复或疫苗接种的时效作用以及生理半衰期等因素，我们建议监测IgG抗体水平作为未来疫苗接种的标准。
